Journal of Clinical Oncology, Vol 17, Issue 10
(October), 1999: 3238-3244
© 1999 American Society for Clinical Oncology
Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptase–Polymerase Chain Reaction in Early-Stage Melanoma Patients
Peter J. Bostick,
Donald L. Morton,
Roderick R. Turner,
Kelly T. Huynh,
He-Jing Wang,
Robert Elashoff,
Richard Essner,
Dave S.B. Hoon
From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA.
Address reprint requests to Dave S.B. Hoon, PhD, Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404; email hoon{at}jwci.org
 |
ABSTRACT
|
|---|
PURPOSE: Detection of micrometastases in the regional tumor-draining lymph nodes is critical for accurate staging and prognosis in melanoma patients. We hypothesized that a multiple-mRNA marker (MM) reverse transcriptase–polymerase chain reaction (RT-PCR) assay would improve the detection of occult metastases in the sentinel node (SN), compared with hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC), and that MM expression is predictive of disease relapse.
PATIENTS AND METHODS: Seventy-two consecutive patients with clinical early-stage melanoma underwent sentinel lymphadenectomy (SLND). Their SNs were serially sectioned and assessed for MAGE-3, MART-1, and tyrosinase mRNA expression by RT-PCR, in parallel with H&E staining and IHC, for melanoma metastases. MM expression in the SNs was correlated with H&E and IHC assay results, standard prognostic factors, and disease-free survival.
RESULTS: In 17 patients with H&E- and/or IHC-positive SNs, 16 (94%) expressed two or more mRNAmarkers. Twenty (36%) of 55 patients with histopathologically negative SNs expressed two or more mRNA markers. By multivariate analysis, patients at increased risk of metastases to the SN had thicker lesions (P = .03), were 60 years of age or younger (P < .05), and/or were MM-positive (P < .001). Patients with histopathologically melanoma-free SNs who were MM-positive, compared with those who were positive for one or fewer mRNA markers, were at increased risk of recurrence (P = .02). Patients who were MM-positive with histopathologically proven metastases in the SN were at greatest risk of disease relapse (P = .01).
CONCLUSION: H&E staining and IHC underestimate the true incidence of melanoma metastases. MM expression in the SN more accurately reflects melanoma micrometastases and is also a more powerful predictor of disease relapse than are H&E staining and IHC alone.
|
INTRODUCTION
|
|---|
THE 5-YEAR SURVIVAL rate for early-stage melanoma (American Joint Committee on Cancer [AJCC] stages I and II) decreases to less than 50% in patients when metastases are identified in their regional lymph nodes (AJCC stage III).1,2 The ability to detect melanoma cells in these lymph nodes is important because accurate staging is useful for guiding adjuvant therapy and directing follow-up procedures.3,4 Serial sectioning and immunohistochemistry (IHC) using HMB-45 and S-100 antibodies improves the detection of occult melanoma cells, compared with conventional hematoxylin and eosin (H&E) staining alone.5,6 More recently, single–mRNA marker reverse transcriptase–polymerase chain reaction (RT-PCR) assays have been used to detect occult melanoma cells in the blood and lymph nodes of melanoma patients whose disease was not found by either H&E or IHC techniques.7-13 However, because melanomas are heterogeneous in the presence and level of tumor-associated gene expression, melanoma cells may go undetected when only a single-marker RT-PCR assay is used.14
Performing RT-PCR, serial sectioning, and IHC on multiple nodes is labor-intensive, especially when the analyses are performed after complete lymph node dissection, during which 10 to 40 lymph nodes may be removed. The sentinel lymphadenectomy (SLND) technique, which was pioneered at the John Wayne Cancer Institute (JWCI) for the treatment of melanoma, identifies the first node to receive melanoma cells from the primary tumor.5 SLND allows for a more focused and extensive pathologic analysis of one or two nodes instead of all nodes in the draining lymphatic basin.5,15,16 In our experience, if the sentinel node (SN) does not contain melanoma cells, then the probability that a nonsentinel node in the draining lymphatic basin contains melanoma cells is less than 1%.5 We have developed a multiple-mRNA marker (MM) RT-PCR assay that uses MAGE-3, MART-1, and tyrosinase mRNA as markers to detect occult melanoma cells in frozen sections of SNs from melanoma patients. These three markers were selected for the MM assay on the basis of their frequency of expression and specificity in primary and metastatic melanoma tumors.14,17
Currently, the patients with early-stage melanoma who will subsequently relapse and die of their disease are unknown. Identifying a subset of these patients who are at risk of recurrence would potentially aid in stratifying these patients into earlier and more aggressive adjuvant therapy. We hypothesized that an MM RT-PCR assay would improve the detection of occult melanoma cells in the SN, compared with H&E staining and IHC, and that MM expression in the SN correlates with an increase in the risk of disease relapse.
|
PATIENTS AND METHODS
|
|---|
Established JWCI melanoma cell lines were used as positive controls for the RT-PCR assay.14,17 Surgical specimens were collected and dissected under stringent "nucleic acid–free" conditions to prevent RNA contamination. SLND was performed in clinical early-stage melanoma patients, as previously described.5 Clinical early-stage melanoma patients are defined as those patients with no clinical evidence of regional or metastatic disease. After the patients provided informed consent, lymph nodes obtained from patients undergoing noncancer surgery (cholecystectomy and tonsillectomy) were used as negative controls in the RT-PCR assay.18 Ten milliliters of blood was collected in sodium citrate–containing tubes from healthy donor volunteers as previously described, and the samples were used as negative controls.14 The blood was centrifuged using a density gradient solution, and nucleated cells in the blood were collected for RNA isolation, as previously described.17
Histopathologic examination and MM RT-PCR analysis were performed on each SN as shown in Fig 1. Each SN was bisected, and an 8-µm imprint slide was then prepared from the tissue surface and stained with Diff-Quik I & II (Dade International, Miami, FL) for the pathologist's intraoperative diagnosis. If melanoma cells were identified in the frozen section, a complete lymph node dissection was then performed. Six immediately adjacent frozen sections were cut on the cryostat to a thickness of 12 µm each and stored at -80°C until they were assessed for melanoma cells by RT-PCR. For RT-PCR analysis, we also determined the necessary amount of mRNA that could consistently be isolated from a minimum number of frozen sections of SN. An additional 8-µm frozen section of tissue was examined by Diff-Quik staining. The remainder of the bisected node was then placed in 10% formalin and embedded in paraffin, and 4-µm–thick sections were examined with H&E staining. If no melanoma cells were identified by H&E staining, an adjacent 4-µm–thick section was evaluated by use of antibodies to HMB-45 and S-100 proteins. This paraffin-section evaluation was performed at two different levels separated by approximately 40 µm. In a retrospective analysis, all SNs that were initially histopathologically melanoma-free were reassessed for occult metastases by taking step-sections at two additional levels, separated by 40 µm, and examining them with H&E staining and IHC. The frequency of capsular nevi and nerve cells in histopathologically melanoma-free SNs was determined because these cells may be potential sources of tyrosinase mRNA expression. Lymph nodes obtained from non–cancer patients were confirmed to be cancer-free by H&E staining, with the remainder of the node used for RT-PCR analysis.
View larger version (39K):
[in this window]
[in a new window]
|
Fig 1. A schematic diagram depicting bisection of the SN (A), serial sectioning of the SN (B), and layering of frozen sections on a slide (C) for RT-PCR.
|
|
TRI-REAGENT (Molecular Research Center, Cincinnati, OH) was used to isolate total RNA from cell lines, primary melanoma biopsy specimens, frozen-section SNs, normal donor blood, and lymph nodes from non–cancer patients as previously described.17,18 Pellet Paint Co-Precipitant (Novagen, Madison, WI) was used as a carrier for RNA precipitation in the SN frozen sections. The resulting RNA pellet can easily be visualized by its pink color, and, in addition, Pellet Paint does not interfere with the RT-PCR assay. The integrity of all RNA samples was verified by performing RT-PCR and ethidium bromide gel electrophoresis for porphobilinogen deaminase mRNA expression (housekeeping gene). Tissue processing, RNA extraction, RT-PCR assay set-up, and post–PCR-product analyses were performed in separate designated rooms and buildings to prevent cross-contamination, as previously reported.17
Optimal RT-PCR conditions were carried out as previously described.17 All RT reactions were carried out with oligo-dT priming, using 1 µg of RNA. The PCR conditions and primer sequences for MAGE-3, MART-1, and tyrosinase were as previously described; optimal annealing temperatures were 55°C, 60°C, and 55°C, respectively.17,19 Primer sequences designed for each marker spanned at least 1 intron region. PCR reactions were set up in an Omni thermocycler (Hybaid, Middlesex, United Kingdom). The RT-PCR cDNA products of MAGE-3, MART-1, and tyrosinase were 423, 252, and 284 base pairs, respectively. Marker-specific cDNA probes were used for Southern blot analyses of RT-PCR products.17 Each experiment set-up included respective positive and negative controls for each procedure. If known positive or negative control samples did not yield the expected results, the assay was considered invalid and was repeated for verification. A positive result in the RT-PCR assay is considered to be the expression of at least two mRNA markers, as previously described.14
The  2 test (or Student's t test for continuous variables) and logistic regression model, using stepwise procedure, were used to assess the correlation of clinicopathologic risk factors and mRNA expression with the histopathology of the SNs. Multivariate analysis, using the Cox proportional hazards regression model, was also performed to examine the association of clinicopathologic risk factors and number of mRNA markers expressed with disease recurrence. Disease-free survival curves were constructed using the Kaplan-Meier method, and the log-rank test was used to test the equality of the curves. P values less than .05 were referred to as significant.20 All statistical analyses were based on the results from the initial analysis of the SN by H&E staining and/or IHC, and RT-PCR.
|
RESULTS
|
|---|
Previously, we demonstrated the specificity and frequency of the melanoma RT-PCR markers in cell lines and melanoma biopsy specimens.17,19 The optimal marker combination for the assay was chosen after extensive analysis of several markers. The marker combination was chosen on the basis of specificity, sensitivity, and potential clinicopathologic utility. In the ten primary melanomas assessed, four (40%) expressed MAGE-3, eight (80%) expressed tyrosinase, and ten (100%) expressed MART-1. None of the three mRNA markers were expressed under the assay's optimal conditions in normal lymph nodes (n = 10) or blood (n = 25) obtained from healthy volunteer donors.
Ninety-three SNs were obtained from 72 clinical early-stage melanoma patients who underwent SLND. All of the samples assessed were positive for porphobilinogen deaminase. No single mRNA marker was expressed in all patients with histopathologically proven melanoma cells in the SN, as previously reported from assessments of melanoma biopsy specimens (primary and metastatic).14,17 Of the 17 patients with histopathologically proven melanoma cells (14 detected by H&E staining, three by IHC alone) in the SN, MAGE-3, MART-1, and tyrosinase were expressed in the SNs of 12 (71%), 15 (88%), and 12 (71%) patients, respectively. Of the 55 patients with histopathologically proven melanoma-free SNs, 24 (44%) expressed MAGE-3, 20 (36%) expressed MART-1, and 16 (29%) expressed tyrosinase. At least two mRNA markers were expressed in 16 (94%) of 17 patients with histopathologically proven metastases and in 20 (36%) of 55 patients with histopathologically proven melanoma-free SNs.
A retrospective analysis of all histopathologically proven melanoma-free SNs (n = 55) was performed by serially resectioning the paraffin-embedded SNs at two different levels and performing H&E staining and IHC analyses. In three (5%) of 55 patients, additional occult melanoma cells were identified; all three cases had SNs that expressed two or more mRNA markers. Therefore, 10% of patients (six of 58) had metastases detected in the SN by IHC alone (three patients in the initial analysis, three patients in the retrospective analysis). Similarly, the single histopathologically positive but RT-PCR–negative node was retested by RT-PCR and shown to remain negative. Capsular nevi, which stained both HMB-45– and S-100–positive, were identified in eight (15%) of 55 patients. Tyrosinase was expressed in only two of these patients. Nerve cells that stained S-100–positive but HMB-45–negative were identified in all SNs.
By univariate analysis, patients with thicker lesions (P < .04), 60 years of age or younger (P = .04), and SNs that expressed MMs (P = .001) were more likely to have histopathologically proven metastases in the SN (Table 1). The mean Breslow thickness in patients with metastases to the SN was 2.1 ± 1.0 mm, compared with 1.5 ± 1.2 mm in patients without metastases. In patients with metastases to the SN, 82% (14 of 17) were 60 years of age or younger, compared with 18% (three of 17) who were older than 60 years of age. MMs were expressed more frequently when SNs contained metastases (94%) than when SNs were melanoma-free (36%). A logistic regression model using a stepwise procedure correlated risk factors (Table 1) with SN metastases. By multivariate analysis, patients at increased risk of metastases to the SN had thicker lesions (P = .03), were 60 years of age or younger (P < .05), and/or expressed MMs (P < .001).
In a mean follow-up period of 12 months, there have been eight recurrences (11%), which include two deaths (3%). In the 35 patients with SNs that were both histopathologically melanoma-free and one or fewer mRNA markers expressed, there were no recurrences. In the 20 patients with SNs that were histopathologically melanoma-free but which expressed two or more mRNA markers, 15% (three of 20) had recurrence of disease. In the 16 patients with histopathologically proven metastases and two or more mRNA markers expressed in the SN, 31% (five of 16) have relapsed. Four of these patients had metastases detected in the SN by H&E staining, and one patient had metastases detected by IHC alone. The patient who had histopathologically proven metastases to the SN but no mRNA marker expression has not relapsed. In the two patients who died of metastatic melanoma, MMs were expressed in the SNs, one of which was histopathologically melanoma-free.
By univariate analysis, MM expression in the SN was a strong predictor of recurrence of disease (Table 2). Multivariate analysis, using a Cox proportional hazards regression model, was also performed to examine the association of the risk factors listed in Table 2 with disease-free survival. Only the number of mRNA markers expressed in the SN was selected by the stepwise procedure as a significant predictor for recurrence of disease (P = .02). The Kaplan-Meier curve in Fig 2 demonstrates that patients whose SNs expressed MMs had a shorter disease-free survival, compared with those whose SNs expressed one or fewer mRNA markers. Patients with histopathologically melanoma-free SNs that expressed MMs, compared with those whose SNs expressed one or fewer mRNA markers, were at increased risk of disease relapse (Fig 3). The patients who were at greatest risk of early disease relapse were those with histopathologically proven melanoma metastases to the SN and MM expression. When patients with histopathologically positive or negative SNs that expressed multiple markers were compared, there was no difference in disease-free relapse (P = .48).
View larger version (11K):
[in this window]
[in a new window]
|
Fig 2. Disease-free survival for RT-PCR marker expression in the SN. Kaplan-Meier curves demonstrate that patients expressing two to three markers (n = 36) are at increased risk (P = .005) of disease relapse, compared with those expressing one or no markers (n = 36).
|
|
View larger version (11K):
[in this window]
[in a new window]
|
Fig 3. Correlation of SN histopathology and RT-PCR marker expression to disease-free survival. (A) Group A: histopathologically negative, zero to one mRNA marker–positive SNs (n = 35); (B) Group B: histopathologically negative, two to three mRNA markers–positive SNs (n = 20); (C) Group C: histopathologically positive, two to three mRNA markers–positive SNs (n = 16). Kaplan-Meier curves demonstrate that group B subjects were at increased risk of disease relapse (P = .02), compared with group A subjects. When all three categories were compared, group C subjects were at greatest risk of disease relapse (P = .01).
|
|
|
DISCUSSION
|
|---|
Metastasis to the regional lymph nodes is one of the most important prognostic factors in patients with cutaneous melanoma.1 The 5-year survival rate for localized melanoma (AJCC stages I and II) is approximately 80% but decreases to 40% to 50% with microscopic lymph node involvement (AJCC stage III).1,2 Accurate staging of the lymphatic basin(s) draining the primary melanoma has become increasingly important because adjuvant therapy, which has been shown to improve survival, is now available.3,4,21,22 The potential therapeutic benefit of adjuvant therapy for melanoma patients with lymph node metastases stresses the importance of accurate staging of the lymphatic basin.
A more extensive and sensitive analysis of lymph nodes in the lymphatic basin by serial sectioning, IHC, and now RT-PCR can improve the detection of occult tumor cells, compared with conventional sectioning using H&E staining alone.5-7,23 However, this intense investigation for metastases is not always pathologically feasible when these techniques are performed on all lymph nodes removed by elective lymph node dissection.24 Analysis of the SN, which accurately predicts the histopathology of the remaining lymphatic basin in 99% of cases, resolves the problem of assessing the entire lymphatic basin.15,16 When SLND is performed at experienced institutions, the SN can be accurately identified in 98% or more of cases.15,16,25-27 SLND combined with MM RT-PCR analysis provides a powerful tool for staging the draining lymphatic basin in melanoma patients.
In this study, the high specificity of the MM RT-PCR assay was first demonstrated by the fact that none of the mRNA markers were expressed in noncancerous lymph nodes or blood obtained from normal healthy donors. After resectioning all SNs that were initially histopathologically melanoma-free, we identified capsular nevi, a potential source of tyrosinase mRNA expression, in 15% (eight of 55) of patients. This incidence of capsular nevi falls within the 4% to 22% range reported by other institutions.28 However, tyrosinase mRNA was detected in only two of these patients, one of whom subsequently died. This suggests that not all capsular nevi have detectable tyrosinase mRNA by RT-PCR and that the presence of capsular nevi does not exclude the possibility micrometastatic disease. Capsular nevi have a low proliferative/metabolic rate, and, therefore, tyrosinase mRNA may go undetected by RT-PCR because it is being expressed at such a low level or not at all. Nerve cells have also been reported as a source of tyrosinase expression.19,28 On resectioning the histopathologically melanoma-free SNs, we identified nerve cells in 100% of the cases. However, only 28% of these SNs expressed tyrosinase; thus it is highly unlikely that nerve cells represent the source of tyrosinase mRNA detected in SNs. These findings demonstrate the high specificity of the MM RT-PCR assay under the optimal established conditions.
To determine the sensitivity of the MM RT-PCR assay in detecting occult melanoma cells, expression in the SN must be compared with conventional histopathology, which is the current gold standard for diagnosis. No single mRNA marker was expressed in all SNs with histopathologically proven metastases. Single-marker RT-PCR assays with 100% sensitivity may be compromised by a low specificity.7-10 Because melanoma is heterogeneous in tumor gene expression, it is not surprising that a single-marker assay is unable to detect 100% of occult melanoma cells. In this study, we demonstrated that the use of MMs improves the sensitivity of the assay in detecting melanoma cells. Additionally, the level of mRNA expression of a specific gene by melanoma cells diluted among the mRNA of normal cells may be too low for detection, even when amplified by RT-PCR. A sampling error may also occur when the lymph node is assessed for histopathologic and RT-PCR analysis. The sensitivity in detecting micrometastases even with the combined sensitive techniques of IHC and RT-PCR can still be limited by the number of serial sections assessed, as was demonstrated in this study. To minimize this sampling error, each SN was bisected and serially sectioned for both histopathologic and molecular analysis as shown in Fig 1. Bisecting and serially sectioning the SN is logistically more rational, compared with "arbitrarily" sampling a piece of lymph node for molecular and histopathologic analysis. The likelihood of 100% concordance in comparing histopathology to RT-PCR, using the technique of "arbitrarily" sampling half of the SN for each type of assay, is very low. This error would be further compounded when using a single-marker assay, whose frequency of expression is less than 100% in melanoma biopsies. From our experience at JWCI, the majority of SNs from early-stage melanoma patients that are positive for melanoma will have only small micrometastases or occult melanoma cells. By combining the MM RT-PCR assay with the techniques of bisecting and serially sectioning the SN, the sensitivity of this assay in detecting histopathologically proven metastases in the SN was 94%.
The clinicopathologic importance of melanoma cells detected in the SN by RT-PCR has not been clearly established to date. However, Shivers et al,7 recently demonstrated a significantly decreased disease-free survival and overall survival in patients with histopathologically negative SNs that expressed mRNA tyrosinase, compared with those without tyrosinase expression. In our study, we demonstrated that patients whose SNs expressed MMs in comparison to one or fewer mRNA markers were more likely to have metastases to the SN (Table 1). In addition, patients with histopathologically melanoma-free SNs with MM expression were at greater risk of disease relapse, compared with those expressing one or fewer mRNA markers. By multivariate analysis, MM expression in the SN was also the strongest predictor of disease relapse, even when compared with the histopathology of the SN (P = .02). These findings indicate that MM expression in the SN correlates with a poor prognosis. Therefore, the 36% (20 of 55) of patients in this study with histopathologically melanoma-free SNs are at increased risk of disease relapse. It is this subgroup of patients who may benefit from aggressive surveillance for disease recurrence and stratification into more appropriate adjuvant therapy. This should ultimately improve survival of this patient subpopulation. In addition, the 64% (35 of 55) of patients with histopathologically proven melanoma-free SNs that expressed one or fewer mRNA markers represent a low-risk group for disease relapse who may be spared from the side effects of postadjuvant therapy.
In summary, H&E staining and IHC underestimate the true incidence of melanoma metastases. The MM RT-PCR assay combined with SLND and serial sectioning of the bisected SN is a more rigorous and highly accurate approach leading to ultrastaging of the tumor-draining lymphatic basin of melanoma patients. Our early findings indicate that MM expression in the SN not only more accurately reflects melanoma micrometastases, compared with H&E and IHC, but is also a more powerful predictor of disease relapse.
|
ACKNOWLEDGMENTS
|
|---|
Supported by National Institutes of Health National Cancer Institute Program Project grants CA 29605 and CA 12582. P.J.B. also received a fellowship merit award from the American Society for Clinical Oncology
We thank the clinical staff of the John Wayne Cancer Institute. We also thank D. Chi and C. Kuo for their technical assistance and G. Ryon for his pathology technical expertise.
|
NOTES
|
|---|
Presented in part at the Thirty-Fourth Annual Meeting of the American Society for Clinical Oncology in Los Angeles, CA, May 16-19, 1998.
|
REFERENCES
|
|---|
1.
Buzaid AC, Tinoco LA, Jendiroba D, et al: Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol13:2361-2368, 1995[Abstract/Free Full Text]
2.
Morton DL, Wanek L, Nizze JA, et al: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg214:491-499, 1991[Medline]
3.
Kirkwood JM: Adjuvant IFN 2 therapy of melanoma. Lancet351:1901-1903, 1998[Medline]
4.
Hoon DS, Okamoto T, Wang HJ, et al: Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol16:1430-1437, 1998[Abstract/Free Full Text]
5.
Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg127:392-399, 1992[Abstract/Free Full Text]
6.
Cochran AJ, Wen DR, Herschman HR, et al: Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int J Cancer34:159-163, 1984[Medline]
7.
Shivers SC, Wang X, Li W, et al: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA280:1410-1415, 1998[Abstract/Free Full Text]
8.
Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet338:1227-1229, 1991[Medline]
9.
Doi F, Chi DDJ, Charuworn BB, et al: Detection of ß-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer65:454-459, 1996[Medline]
10.
Kuo CT, Bostick PJ, Irie RF, et al: Assessment of messenger RNA of ß1  4-N-acetylgalactosaminyltransferase as a molecular marker for metastatic melanoma. Clin Cancer Res4:411-418, 1998[Abstract/Free Full Text]
11.
Jung FA, Buzaid AC, Ross MI, et al: Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol15:2826-2831, 1997[Abstract]
12.
Kunter U, Buer J, Probst M, et al: Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst88:590-594, 1996[Abstract/Free Full Text]
13.
Mellado B, Colomer D, Castel T, et al: Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. J Clin Oncol14:2091-2097, 1996[Abstract/Free Full Text]
14.
Hoon DS, Wang Y, Dale PS, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol13:2109-2116, 1995[Abstract/Free Full Text]
15.
Morton DL, Wen DR, Foshag LJ, et al: Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol11:1751-1756, 1993[Abstract/Free Full Text]
16.
Morton DL, Wen D-R, Cochran AJ: Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. Surg Oncol Clin North Am1:247-259, 1992
17.
Sarantou T, Chi DD, Garrison DA, et al: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res57:1371-1376, 1997[Abstract/Free Full Text]
18.
Bostick PJ, Chatterjee S, Chi DD, et al: Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol16:2632-2640, 1998[Abstract]
19.
Chi DD, Merchant RE, Rand R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol150:2143-2152, 1997[Abstract]
20.
Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer-Verlag, 1997
21.
Morton DL, Barth A: Vaccine therapy for malignant melanoma. CA Cancer J Clin46:225-244, 1996[Medline]
22.
Livingston P: Ganglioside vaccines with emphasis on GM2. Semin Oncol25:636-645, 1998[Medline]
23.
Ludwig Trial, International Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet335:1565-1568, 1990[Medline]
24.
Balch CM, Soong SJ, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg224:255-266, 1996[Medline]
25.
Bostick P, Essner R, Glass E, et al: Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg134:43-49, 1999[Abstract/Free Full Text]
26.
Leong SP, Steinmetz I, Habib FA, et al: Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg132:666-673, 1997[Abstract/Free Full Text]
27.
Karakousis CP, Velez AF, Spellman JE, et al: The technique of sentinel node biopsy. Eur J Surg Oncol22:271-275, 1996[Medline]
28.
Carson KF, Wen DR, Li PX, et al: Nodal nevi and cutaneous melanomas. Am J Surg Pathol20:834-840, 1996[Medline]
Submitted March 1, 1999;
accepted June 10, 1999.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. M. Hilari, C. Mangas, L. Xi, C. Paradelo, C. Ferrandiz, S. J. Hughes, C. Yueh, I. Altomare, W. E. Gooding, and T. E. Godfrey
Molecular Staging of Pathologically Negative Sentinel Lymph Nodes from Melanoma Patients Using Multimarker, Quantitative Real-Time RT-PCR
Ann. Surg. Oncol.,
January 1, 2009;
16(1):
177 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mocellin, D. S.B. Hoon, P. Pilati, C. R. Rossi, and D. Nitti
Sentinel Lymph Node Molecular Ultrastaging in Patients With Melanoma: A Systematic Review and Meta-Analysis of Prognosis
J. Clin. Oncol.,
April 20, 2007;
25(12):
1588 - 1595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Chen, D. M. Iddings, R. P. Scheri, and A. J. Bilchik
Lymphatic Mapping and Sentinel Node Analysis: Current Concepts and Applications
CA Cancer J Clin,
September 1, 2006;
56(5):
292 - 309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mangas, J. M. Hilari, C. Paradelo, J. Rex, M. T. Fernandez-Figueras, M. Fraile, A. Alastrue, and C. Ferrandiz
Prognostic Significance of Molecular Staging Study of Sentinel Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase in Melanoma Patients
Ann. Surg. Oncol.,
July 1, 2006;
13(7):
910 - 918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Scoggins, M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, B. S. Davidson, J. J. Sussman, et al.
Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma
J. Clin. Oncol.,
June 20, 2006;
24(18):
2849 - 2857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner
Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
J. Nucl. Med.,
June 1, 2006;
47(6):
957 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J.C.L.M. Vuylsteke, B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, P. G.J.T.B. Wijnands, J. B.A.G. Haanen, R. J. Scheper, and T. D. de Gruijl
Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content.
Clin. Cancer Res.,
May 1, 2006;
12(9):
2826 - 2833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vaquerano, W. G. Kraybill, D. L. Driscoll, R. Cheney, and J. M. Kane III
American Joint Committee on Cancer Clinical Stage as a Selection Criterion for Sentinel Lymph Node Biopsy in Thin Melanoma
Ann. Surg. Oncol.,
February 1, 2006;
13(2):
198 - 204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. Molenkamp, R. J.C.L.M. Vuylsteke, P. A.M. van Leeuwen, S. Meijer, W. Vos, P. G.J.T.B. Wijnands, R. J. Scheper, and T. D. de Gruijl
Matched Skin and Sentinel Lymph Node Samples of Melanoma Patients Reveal Exclusive Migration of Mature Dendritic Cells
Am. J. Pathol.,
November 1, 2005;
167(5):
1301 - 1307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Romanini, G. Manca, D. Pellegrino, R. Murr, S. Sarti, F. Bianchi, A. AlSharif, C. Orlandini, V. Zucchi, M. Castagna, et al.
Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome
Ann. Onc.,
November 1, 2005;
16(11):
1832 - 1840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Coit
In-Transit Recurrence After Sentinel Lymph Node Biopsy in Melanoma: Primum Non Nocere
Ann. Surg. Oncol.,
August 1, 2005;
12(8):
575 - 578.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Sahni, A Robson, G Orchard, R Szydlo, A V Evans, and R Russell-Jones
The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status
J. Clin. Pathol.,
July 1, 2005;
58(7):
715 - 721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Ferris, L. Xi, S. Raja, J. L. Hunt, J. Wang, W. E. Gooding, L. Kelly, J. Ching, J. D. Luketich, and T. E. Godfrey
Molecular Staging of Cervical Lymph Nodes in Squamous Cell Carcinoma of the Head and Neck
Cancer Res.,
March 15, 2005;
65(6):
2147 - 2156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Mori, J. Kim, T. Yamano, H. Takeuchi, S. Huang, N. Umetani, K. Koyanagi, and D. S.B. Hoon
Epigenetic Up-regulation of C-C Chemokine Receptor 7 and C-X-C Chemokine Receptor 4 Expression in Melanoma Cells
Cancer Res.,
March 1, 2005;
65(5):
1800 - 1807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. N. Abrahamsen, B. Sandahl Sorensen, E. Nexo, S. J. Hamilton-Dutoit, J. Larsen, and T. Steiniche
Pathologic Assessment of Melanoma Sentinel Nodes: A Role for Molecular Analysis Using Quantitative Real-Time Reverse Transcription-PCR for MART-1 and Tyrosinase Messenger RNA
Clin. Cancer Res.,
February 15, 2005;
11(4):
1425 - 1433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring
Molecular Diagnosis of Cutaneous Diseases
Arch Dermatol,
February 1, 2005;
141(2):
225 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. C. L. M. Vuylsteke, B. G. Molenkamp, H. A. Gietema, P. A. M. van Leeuwen, P. G. J. T. B. Wijnands, W. Vos, P. J. van Diest, R. J. Scheper, S. Meijer, and T. D. de Gruijl
Local Administration of Granulocyte/Macrophage Colony-stimulating Factor Increases the Number and Activation State of Dendritic Cells in the Sentinel Lymph Node of Early-Stage Melanoma
Cancer Res.,
November 15, 2004;
64(22):
8456 - 8460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shivers, M. Alsarraj, R. Guiliano, J. Jakub, S. Pendas, and D. Reintgen
Molecular Staging of Melanoma
Ann. Surg. Oncol.,
November 1, 2004;
11(11):
953 - 954.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wlodzimierz, P. Rutkowski, Z. I. Nowecki, J. Kulik, A. Nasierowska-Guttmejer, and J. A. Siedlecki
Detection of Melanoma Cells in the Lymphatic Drainage after Lymph Node Dissection in Melanoma Patients by Using Two-Marker Reverse Transcriptase-Polymerase Chain Reaction Assay
Ann. Surg. Oncol.,
November 1, 2004;
11(11):
988 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. S. Kammula, R. Ghossein, S. Bhattacharya, and D. G. Coit
Serial Follow-Up and the Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction--Staged Sentinel Lymph Nodes From Melanoma Patients
J. Clin. Oncol.,
October 1, 2004;
22(19):
3989 - 3996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. N. Abrahamsen, E. Nexo, T. Steiniche, S. J. Hamilton-Dutoit, and B. S. Sorensen
Quantification of Melanoma mRNA Markers in Sentinel Nodes: Pre-Clinical Evaluation of a Single-Step Real-Time Reverse Transcriptase-Polymerase Chain Reaction Assay
J. Mol. Diagn.,
August 1, 2004;
6(3):
253 - 259.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. B. Faries, R. J. Bleicher, X. Ye, R. Essner, and D. L. Morton
Lymphatic Mapping and Sentinel Lymphadenectomy for Primary and Metastatic Pulmonary Malignant Neoplasms
Arch Surg,
August 1, 2004;
139(8):
870 - 877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takeuchi, D. L. Morton, C. Kuo, R. R. Turner, D. Elashoff, R. Elashoff, B. Taback, A. Fujimoto, and D. S.B. Hoon
Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients
J. Clin. Oncol.,
July 1, 2004;
22(13):
2671 - 2680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Pawlik, M. I. Ross, and J. E. Gershenwald
Lymphatic Mapping in the Molecular Era
Ann. Surg. Oncol.,
April 1, 2004;
11(4):
362 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takeuchi, A. Fujimoto, M. Tanaka, T. Yamano, E. Hsueh, and D. S. B. Hoon
CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells
Clin. Cancer Res.,
April 1, 2004;
10(7):
2351 - 2358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fujimoto, H. Takeuchi, B. Taback, E. C. Hsueh, D. Elashoff, D. L. Morton, and D. S. B. Hoon
Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma
Cancer Res.,
March 15, 2004;
64(6):
2245 - 2250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Morton
Sentinel Node Mapping and an International Sentinel Node Society: Current Issues and Future Directions
Ann. Surg. Oncol.,
March 1, 2004;
11(3_suppl):
137S - 143S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takeuchi, B. Taback, C. Kuo, and D. S. B. Hoon
Clinicopathological Utility of Molecular Staging for Melanoma Patients Undergoing Sentinel Lymphadenectomy
Ann. Surg. Oncol.,
March 1, 2004;
11(3_suppl):
152S - 155S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Reintgen, J. W. Jakub, S. Pendas, G. Swor, R. Giuliano, and S. Shivers
The Staging of Malignant Melanoma and the Florida Melanoma Trial
Ann. Surg. Oncol.,
March 1, 2004;
11(3_suppl):
186S - 191S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. L. Leong
Paradigm of Metastasis for Melanoma and Breast Cancer Based on the Sentinel Lymph Node Experience
Ann. Surg. Oncol.,
March 1, 2004;
11(3_suppl):
192S - 197S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Krown and P. B. Chapman
Defining Adequate Surgery for Primary Melanoma
N. Engl. J. Med.,
February 19, 2004;
350(8):
823 - 825.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Kuo, D. S.B. Hoon, H. Takeuchi, R. Turner, H.-J. Wang, D. L. Morton, and B. Taback
Prediction of Disease Outcome in Melanoma Patients by Molecular Analysis of Paraffin-Embedded Sentinel Lymph Nodes
J. Clin. Oncol.,
October 1, 2003;
21(19):
3566 - 3572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Hess, E. A. Seftor, R. E. B. Seftor, and M. J. C. Hendrix
Phosphoinositide 3-Kinase Regulates Membrane Type 1-Matrix Metalloproteinase (MMP) and MMP-2 Activity during Melanoma Cell Vasculogenic Mimicry
Cancer Res.,
August 15, 2003;
63(16):
4757 - 4762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Wascher, D. L. Morton, C. Kuo, R. M. Elashoff, H.-J. Wang, M. Gerami, and D. S.B. Hoon
Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated With a Melanoma Vaccine
J. Clin. Oncol.,
July 1, 2003;
21(13):
2558 - 2563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ribuffo, A. Gradilone, M. Vonella, S. Chiummariello, E. Cigna, N. Haliassos, R. Massa, I. Silvestri, S. Calvieri, L. Frati, et al.
Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction-Negative Sentinel Nodes in Malignant Melanoma
Ann. Surg. Oncol.,
May 1, 2003;
10(4):
396 - 402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Spugnardi, S. Tommasi, R. Dammann, G. P. Pfeifer, and D. S. B. Hoon
Epigenetic Inactivation of RAS Association Domain Family Protein 1 (RASSF1A) in Malignant Cutaneous Melanoma
Cancer Res.,
April 1, 2003;
63(7):
1639 - 1643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Harden, Y. Tokumaru, W. H. Westra, S. Goodman, S. A. Ahrendt, S. C. Yang, and D. Sidransky
Gene Promoter Hypermethylation in Tumors and Lymph Nodes of Stage I Lung Cancer Patients
Clin. Cancer Res.,
April 1, 2003;
9(4):
1370 - 1375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takeuchi, A. Bilchik, S. Saha, R. Turner, D. Wiese, M. Tanaka, C. Kuo, H.-J. Wang, and D. S. B. Hoon
c-MET Expression Level in Primary Colon Cancer: A Predictor of Tumor Invasion and Lymph Node Metastases
Clin. Cancer Res.,
April 1, 2003;
9(4):
1480 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Bilchik, D. T. Nora, L. H. Sobin, R. R. Turner, S. Trocha, D. Krasne, and D. L. Morton
Effect of Lymphatic Mapping on the New Tumor-Node-Metastasis Classification for Colorectal Cancer
J. Clin. Oncol.,
February 15, 2003;
21(4):
668 - 672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Davids, S H Kidson, and G S Hanekom
Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate
Mol. Pathol.,
February 1, 2003;
56(1):
43 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ayyoub, A. Zippelius, M. J. Pittet, D. Rimoldi, D. Valmori, J.-C. Cerottini, P. Romero, F. Lejeune, D. Lienard, and D. E. Speiser
Activation of Human Melanoma Reactive CD8+ T Cells by Vaccination with an Immunogenic Peptide Analog Derived from Melan-A/Melanoma Antigen Recognized by T Cells-1
Clin. Cancer Res.,
February 1, 2003;
9(2):
669 - 677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takeuchi, C. Kuo, D. L. Morton, H.-J. Wang, and D. S. B. Hoon
Expression of Differentiation Melanoma-associated Antigen Genes Is Associated with Favorable Disease Outcome in Advanced-Stage Melanomas
Cancer Res.,
January 15, 2003;
63(2):
441 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gradilone, P. Gazzaniga, D. Ribuffo, S. Scarpa, E. Cigna, F. Vasaturo, U. Bottoni, D. Innocenzi, S. Calvieri, N. Scuderi, et al.
Survivin, bcl-2, bax, and bcl-X Gene Expression in Sentinel Lymph Nodes From Melanoma Patients
J. Clin. Oncol.,
January 15, 2003;
21(2):
306 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Taback, K. Hashimoto, C. T. Kuo, A. Chan, A. E. Giuliano, and D. S. B. Hoon
Molecular Lymphatic Mapping of the Sentinel Lymph Node
Am. J. Pathol.,
October 1, 2002;
161(4):
1153 - 1161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Raja, T. El-Hefnawy, L. A. Kelly, M. L. Chestney, J. D. Luketich, and T. E. Godfrey
Temperature-controlled Primer Limit for Multiplexing of Rapid, Quantitative Reverse Transcription-PCR Assays: Application to Intraoperative Cancer Diagnostics
Clin. Chem.,
August 1, 2002;
48(8):
1329 - 1337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mariani, M. Gipponi, L. Moresco, G. Villa, M. Bartolomei, G. Mazzarol, M. C. Bagnara, A. Romanini, F. Cafiero, G. Paganelli, et al.
Radioguided Sentinel Lymph Node Biopsy in Malignant Cutaneous Melanoma*
J. Nucl. Med.,
June 1, 2002;
43(6):
811 - 827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Raja, J. D. Luketich, L. A. Kelly, W. E. Gooding, S. D. Finkelstein, and T. E. Godfrey
Rapid, quantitative reverse transcriptase-polymerase chain reaction: Application to intraoperative molecular detection of occult metastases in esophageal cancer
J. Thorac. Cardiovasc. Surg.,
March 1, 2002;
123(3):
475 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Taback, A. D. Chan, C. T. Kuo, P. J. Bostick, H.-J. Wang, A. E. Giuliano, and D. S. B. Hoon
Detection of Occult Metastatic Breast Cancer Cells in Blood by a Multimolecular Marker Assay: Correlation with Clinical Stage of Disease
Cancer Res.,
December 1, 2001;
61(24):
8845 - 8850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Godfrey, S. Raja, S. D. Finkelstein, W. E. Gooding, L. A. Kelly, and J. D. Luketich
Prognostic Value of Quantitative Reverse Transcription-Polymerase Chain Reaction in Lymph Node-negative Esophageal Cancer Patients
Clin. Cancer Res.,
December 1, 2001;
7(12):
4041 - 4048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Dubois, S. M. Swetter, M. Atkins, K. McMasters, R. Halbert, S. J. Miller, R. Shiell, and J. Kirkwood
Developing Indications for the Use of Sentinel Lymph Node Biopsy and Adjuvant High-Dose Interferon Alfa-2b in Melanoma
Arch Dermatol,
September 1, 2001;
137(9):
1217 - 1224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Balch, A. C. Buzaid, S.-J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr, J. M. Kirkwood, et al.
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
J. Clin. Oncol.,
August 15, 2001;
19(16):
3635 - 3648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Taback, Y. Fujiwara, H.-J. Wang, L. J. Foshag, D. L. Morton, and D. S. B. Hoon
Prognostic Significance of Circulating Microsatellite Markers in the Plasma of Melanoma Patients
Cancer Res.,
August 1, 2001;
61(15):
5723 - 5726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.M. Acland, C. Healy, E. Calonje, M. O'Doherty, T. Nunan, C. Page, E. Higgins, and R. Russell-Jones
Comparison of Positron Emission Tomography Scanning and Sentinel Node Biopsy in the Detection of Micrometastases of Primary Cutaneous Malignant Melanoma
J. Clin. Oncol.,
May 15, 2001;
19(10):
2674 - 2678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Clary, B. Mann, M. S. Brady, J. J. Lewis, and D. G. Coit
Early Recurrence After Lymphatic Mapping and Sentinel Node Biopsy in Patients With Primary Extremity Melanoma: A Comparison With Elective Lymph Node Dissection
Ann. Surg. Oncol.,
April 1, 2001;
8(4):
328 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Palmieri, P. A. Ascierto, A. Cossu, N. Mozzillo, M. L. Motti, S. M.R. Satriano, G. Botti, C. Caraco, E. Celentano, R. A. Satriano, et al.
Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay
J. Clin. Oncol.,
March 1, 2001;
19(5):
1437 - 1443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Miyashiro, C. Kuo, K. Huynh, A. Iida, D. Morton, A. Bilchik, A. Giuliano, and D. S.B. Hoon
Molecular Strategy for Detecting Metastatic Cancers with Use of Multiple Tumor-specific MAGE-A Genes
Clin. Chem.,
March 1, 2001;
47(3):
505 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Warso, A. J. Maniotis, X. Chen, D. Majumdar, M. K. Patel, A. Shilkaitis, T. K. Das Gupta, and R. Folberg
Prognostic Significance of Periodic Acid-Schiff-positive Patterns in Primary Cutaneous Melanoma
Clin. Cancer Res.,
March 1, 2001;
7(3):
473 - 477.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. J. Bilchik, S. Saha, D. Wiese, J. A. Stonecypher, T. F. Wood, S. Sostrin, R. R. Turner, H.-J. Wang, D. L. Morton, and D. S.B. Hoon
Molecular Staging of Early Colon Cancer on the Basis of Sentinel Node Analysis: A Multicenter Phase II Trial
J. Clin. Oncol.,
February 15, 2001;
19(4):
1128 - 1136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. B. Hoon, P. Bostick, C. Kuo, T. Okamoto, H.-J. Wang, R. Elashoff, and D. L. Morton
Molecular Markers in Blood as Surrogate Prognostic Indicators of Melanoma Recurrence
Cancer Res.,
April 1, 2000;
60(8):
2253 - 2257.
[Abstract]
[Full Text]
|
|
|
|
TOP
ABSTRACT
INTRODUCTION
